Primary and reactivated HHV8 infection and disease after liver transplantation: A prospective study

G. Pietrosi, G. Vizzini, L. Pipitone, G. Di Martino, M. I. Minervini, G. Lo Iacono, P. G. Conaldi, P. Grossi, V. Lamonaca, L. Galatioto, S. Gruttadauria, B. Gridelli

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Human herpesvirus 8 (HHV8) is pathogenic in humans, especially in cases of immunosuppression. We evaluated the risk of HHV8 transmission from liver donors, and its clinical impact in southern Italy, where its seroprevalence in the general population is reported to be as high as 18.3%. We tested 179 liver transplant recipients and their donors for HHV8 antibodies at the time of transplantation, and implemented in all recipients a 12-month posttransplant surveillance program for HHV8 infection. Of the 179 liver transplant recipients enrolled, 10.6% were HHV8 seropositive before transplantation, whereas the organ donor's seroprevalence was 4.4%. Eight seronegative patients received a liver from a seropositive donor, and four of them developed primary HHV8 infection. Two of these patients had lethal nonmalignant illness with systemic involvement and multiorgan failure. Among the 19 HHV8 seropositive recipients, two had viral reactivation after liver transplantation. In addition, an HHV8 seronegative recipient of a seronegative donor developed primary HHV8 infection and multicentric Castleman's disease. In conclusion, primary HHV8 infection transmitted from a seropositive donor to a seronegative liver transplant recipient can cause a severe nonmalignant illness associated with high mortality. Donor screening for HHV8 should be considered in geographic areas with a high prevalence of such infection.

Original languageEnglish
Pages (from-to)2715-2723
Number of pages9
JournalAmerican Journal of Transplantation
Volume11
Issue number12
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Herpesviridae Infections
Human Herpesvirus 8
Liver Transplantation
Prospective Studies
Tissue Donors
Liver
Seroepidemiologic Studies
Transplantation
Donor Selection
Immunosuppression
Italy

Keywords

  • donor screening
  • Donor/recipient matching
  • HHV8
  • HHV8 seroprevalence
  • liver transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Primary and reactivated HHV8 infection and disease after liver transplantation : A prospective study. / Pietrosi, G.; Vizzini, G.; Pipitone, L.; Di Martino, G.; Minervini, M. I.; Lo Iacono, G.; Conaldi, P. G.; Grossi, P.; Lamonaca, V.; Galatioto, L.; Gruttadauria, S.; Gridelli, B.

In: American Journal of Transplantation, Vol. 11, No. 12, 12.2011, p. 2715-2723.

Research output: Contribution to journalArticle

Pietrosi, G, Vizzini, G, Pipitone, L, Di Martino, G, Minervini, MI, Lo Iacono, G, Conaldi, PG, Grossi, P, Lamonaca, V, Galatioto, L, Gruttadauria, S & Gridelli, B 2011, 'Primary and reactivated HHV8 infection and disease after liver transplantation: A prospective study', American Journal of Transplantation, vol. 11, no. 12, pp. 2715-2723. https://doi.org/10.1111/j.1600-6143.2011.03769.x
Pietrosi, G. ; Vizzini, G. ; Pipitone, L. ; Di Martino, G. ; Minervini, M. I. ; Lo Iacono, G. ; Conaldi, P. G. ; Grossi, P. ; Lamonaca, V. ; Galatioto, L. ; Gruttadauria, S. ; Gridelli, B. / Primary and reactivated HHV8 infection and disease after liver transplantation : A prospective study. In: American Journal of Transplantation. 2011 ; Vol. 11, No. 12. pp. 2715-2723.
@article{4ed0dbc399084224b4ce523762f46f40,
title = "Primary and reactivated HHV8 infection and disease after liver transplantation: A prospective study",
abstract = "Human herpesvirus 8 (HHV8) is pathogenic in humans, especially in cases of immunosuppression. We evaluated the risk of HHV8 transmission from liver donors, and its clinical impact in southern Italy, where its seroprevalence in the general population is reported to be as high as 18.3{\%}. We tested 179 liver transplant recipients and their donors for HHV8 antibodies at the time of transplantation, and implemented in all recipients a 12-month posttransplant surveillance program for HHV8 infection. Of the 179 liver transplant recipients enrolled, 10.6{\%} were HHV8 seropositive before transplantation, whereas the organ donor's seroprevalence was 4.4{\%}. Eight seronegative patients received a liver from a seropositive donor, and four of them developed primary HHV8 infection. Two of these patients had lethal nonmalignant illness with systemic involvement and multiorgan failure. Among the 19 HHV8 seropositive recipients, two had viral reactivation after liver transplantation. In addition, an HHV8 seronegative recipient of a seronegative donor developed primary HHV8 infection and multicentric Castleman's disease. In conclusion, primary HHV8 infection transmitted from a seropositive donor to a seronegative liver transplant recipient can cause a severe nonmalignant illness associated with high mortality. Donor screening for HHV8 should be considered in geographic areas with a high prevalence of such infection.",
keywords = "donor screening, Donor/recipient matching, HHV8, HHV8 seroprevalence, liver transplantation",
author = "G. Pietrosi and G. Vizzini and L. Pipitone and {Di Martino}, G. and Minervini, {M. I.} and {Lo Iacono}, G. and Conaldi, {P. G.} and P. Grossi and V. Lamonaca and L. Galatioto and S. Gruttadauria and B. Gridelli",
year = "2011",
month = "12",
doi = "10.1111/j.1600-6143.2011.03769.x",
language = "English",
volume = "11",
pages = "2715--2723",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Primary and reactivated HHV8 infection and disease after liver transplantation

T2 - A prospective study

AU - Pietrosi, G.

AU - Vizzini, G.

AU - Pipitone, L.

AU - Di Martino, G.

AU - Minervini, M. I.

AU - Lo Iacono, G.

AU - Conaldi, P. G.

AU - Grossi, P.

AU - Lamonaca, V.

AU - Galatioto, L.

AU - Gruttadauria, S.

AU - Gridelli, B.

PY - 2011/12

Y1 - 2011/12

N2 - Human herpesvirus 8 (HHV8) is pathogenic in humans, especially in cases of immunosuppression. We evaluated the risk of HHV8 transmission from liver donors, and its clinical impact in southern Italy, where its seroprevalence in the general population is reported to be as high as 18.3%. We tested 179 liver transplant recipients and their donors for HHV8 antibodies at the time of transplantation, and implemented in all recipients a 12-month posttransplant surveillance program for HHV8 infection. Of the 179 liver transplant recipients enrolled, 10.6% were HHV8 seropositive before transplantation, whereas the organ donor's seroprevalence was 4.4%. Eight seronegative patients received a liver from a seropositive donor, and four of them developed primary HHV8 infection. Two of these patients had lethal nonmalignant illness with systemic involvement and multiorgan failure. Among the 19 HHV8 seropositive recipients, two had viral reactivation after liver transplantation. In addition, an HHV8 seronegative recipient of a seronegative donor developed primary HHV8 infection and multicentric Castleman's disease. In conclusion, primary HHV8 infection transmitted from a seropositive donor to a seronegative liver transplant recipient can cause a severe nonmalignant illness associated with high mortality. Donor screening for HHV8 should be considered in geographic areas with a high prevalence of such infection.

AB - Human herpesvirus 8 (HHV8) is pathogenic in humans, especially in cases of immunosuppression. We evaluated the risk of HHV8 transmission from liver donors, and its clinical impact in southern Italy, where its seroprevalence in the general population is reported to be as high as 18.3%. We tested 179 liver transplant recipients and their donors for HHV8 antibodies at the time of transplantation, and implemented in all recipients a 12-month posttransplant surveillance program for HHV8 infection. Of the 179 liver transplant recipients enrolled, 10.6% were HHV8 seropositive before transplantation, whereas the organ donor's seroprevalence was 4.4%. Eight seronegative patients received a liver from a seropositive donor, and four of them developed primary HHV8 infection. Two of these patients had lethal nonmalignant illness with systemic involvement and multiorgan failure. Among the 19 HHV8 seropositive recipients, two had viral reactivation after liver transplantation. In addition, an HHV8 seronegative recipient of a seronegative donor developed primary HHV8 infection and multicentric Castleman's disease. In conclusion, primary HHV8 infection transmitted from a seropositive donor to a seronegative liver transplant recipient can cause a severe nonmalignant illness associated with high mortality. Donor screening for HHV8 should be considered in geographic areas with a high prevalence of such infection.

KW - donor screening

KW - Donor/recipient matching

KW - HHV8

KW - HHV8 seroprevalence

KW - liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=82455188059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82455188059&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2011.03769.x

DO - 10.1111/j.1600-6143.2011.03769.x

M3 - Article

C2 - 21966899

AN - SCOPUS:82455188059

VL - 11

SP - 2715

EP - 2723

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 12

ER -